We are live on ! Find out more
DCM

Defilade Capital Management Portfolio holdings

AUM $747M
This Fund
S&P 500
This Quarter Est. Return
+0.08%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$712M
AUM Growth
-$25.6M
Cap. Flow
-$2.03M
Cap. Flow %
-0.29%
Top 10 Hldgs %
52.57%
Holding
42
New
9
Increased
12
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$53.1M
2
BDX icon
Becton Dickinson
BDX
+$36.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$27.9M
4
PTCT icon
PTC Therapeutics
PTCT
+$26.6M
5
HSIC icon
Henry Schein
HSIC
+$23.5M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$52M
2
NVS icon
Novartis
NVS
+$50M
3
STE icon
Steris
STE
+$34.3M
4
XNCR icon
Xencor
XNCR
+$21.7M
5
PACS icon
PACS Group
PACS
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$16.4B
$11.9M 1.67%
51,895
-33,799
-39% -$7.58M
ALGN icon
27
Align Technology
ALGN
$11.3B
$11.5M 1.62%
67,332
-60,728
-47% -$10.6M
ELDN icon
28
Eledon Pharmaceuticals
ELDN
$272M
$11M 1.54%
3,564,127
+273,677
+8% +$645K
ORIC icon
29
Oric Pharmaceuticals
ORIC
$1.44B
$10.7M 1.5%
+842,928
New +$9.57M
BHVN icon
30
Biohaven
BHVN
$2.56B
$2.67M 0.38%
+315,944
New +$3.46M
MREO
31
Mereo BioPharma
MREO
$44.4M
$2.49M 0.35%
+7,558,756
New +$3.24M
ABBV icon
32
AbbVie
ABBV
$465B
– –
-227,669
Closed -$52M
ATEC icon
33
Alphatec Holdings
ATEC
$1.45B
– –
-626,754
Closed -$13.2M
ATRC icon
34
AtriCure
ATRC
$2.45B
– –
-397,636
Closed -$15.7M
CNMD icon
35
CONMED
CNMD
$1.51B
– –
-104,129
Closed -$4.23M
GKOS icon
36
Glaukos
GKOS
$10.7B
– –
-91,703
Closed -$10.4M
LIVN icon
37
LivaNova
LIVN
$4.41B
– –
-241,413
Closed -$14.9M
NVS icon
38
Novartis
NVS
$299B
– –
-362,816
Closed -$50M
RXST icon
39
RxSight
RXST
$265M
– –
-913,090
Closed -$9.51M
STE icon
40
Steris
STE
$23.1B
– –
-135,307
Closed -$34.3M
TFX icon
41
Teleflex
TFX
$5.88B
– –
-42,850
Closed -$5.23M
XNCR icon
42
Xencor
XNCR
$2.11B
– –
-1,414,755
Closed -$21.7M
1
2

Similar funds

BG
BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return
PCM
Permanent Capital Management Chicago, Illinois $747M AUM 17.94% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $748M AUM 27.21% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $745M AUM 23.99% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $745M AUM 27.52% 1-Year Est. Return
VCM
Virtue Capital Management Brentwood, Tennessee $749M AUM 40.13% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $745M AUM 25.89% 1-Year Est. Return
CCME
CIBC Capital Markets (Europe) Luxembourg $745M AUM

Defilade Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Defilade Capital Management held 42 positions worth $712M, down 3.5% from $738M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Defilade Capital Management's Q1 2026 filing shows 9 new, 12 increased, 10 reduced and 11 closed positions. Its largest new stake was Zimmer Biomet: 579,161 shares worth $52.4M. The largest sale was AbbVie, an estimated $52M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Defilade Capital Management's largest Q1 2026 buy was Zimmer Biomet: 579,161 shares worth $52.4M.
  • Defilade Capital Management added most to Becton Dickinson in Q1 2026, an estimated $36.3M increase.
  • Defilade Capital Management's biggest Q1 2026 reduction was PACS Group, cutting an estimated $19.9M.
  • Defilade Capital Management fully exited AbbVie in Q1 2026, selling an estimated $52M.
  • Defilade Capital Management's ten largest holdings make up 53% of its $712M portfolio in Q1 2026.
  • Defilade Capital Management opened 9 new positions and closed 11 in Q1 2026.
  • Defilade Capital Management's portfolio value fell 3.5% quarter-over-quarter to $712M.

Based on Defilade Capital Management's 13F filing for Q1 2026, filed 14 May 2026.